These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 24565604)

  • 21. The association of rituximab and a thrombopoietin receptor agonist in high-risk refractory immune thrombocytopenic purpura.
    Veneri D; Soligo L; Pizzolo G; Ambrosetti A
    Blood Transfus; 2015 Oct; 13(4):694-5. PubMed ID: 26057496
    [No Abstract]   [Full Text] [Related]  

  • 22. Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura.
    Newland A
    Eur J Haematol Suppl; 2009 Mar; (71):20-5. PubMed ID: 19200304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of romiplostim in a hemodialysis patient with primary immune thrombocytopenia.
    Al-Jafar H; Giagounidis A; El-Rashaid K; Al-Ali M; Hakim AA
    Ann Pharmacother; 2012 Nov; 46(11):e31. PubMed ID: 23115229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report.
    Sivera P; Ruella M; Gueli A; Hu H; Wade M; Tarella C
    Blood Coagul Fibrinolysis; 2012 Jun; 23(4):331-4. PubMed ID: 22343685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.
    Khellaf M; Michel M; Quittet P; Viallard JF; Alexis M; Roudot-Thoraval F; Cheze S; Durand JM; Lefrère F; Galicier L; Lambotte O; Panelatti G; Slama B; Damaj G; Sebahoun G; Gyan E; Delbrel X; Dhedin N; Royer B; Schleinitz N; Rossi JF; Mahévas M; Languille L; Bierling P; Godeau B
    Blood; 2011 Oct; 118(16):4338-45. PubMed ID: 21832276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
    Chouhan JD; Herrington JD
    Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Romiplostim as early treatment for refractory primary immune thrombocytopenia.
    Contis A; Lazaro E; Greib C; Pellegrin JL; Viallard JF
    Int J Hematol; 2013 Nov; 98(5):520-4. PubMed ID: 24068656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care.
    Kuter DJ; Mathias SD; Rummel M; Mandanas R; Giagounidis AA; Wang X; Deuson RR
    Am J Hematol; 2012 May; 87(5):558-61. PubMed ID: 22460421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).
    Bussel JB; Hsieh L; Buchanan GR; Stine K; Kalpatthi R; Gnarra DJ; Ho RH; Nie K; Eisen M
    Pediatr Blood Cancer; 2015 Feb; 62(2):208-213. PubMed ID: 25345874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful treatment of refractory secondary immune thrombocytopenia (antiphospholipid antibody syndrome-associated) with the combination of rituximab and romiplostim at the cost of severe bone pain: A case report and review of literature.
    Yassa G; Shakir AR; Jagarlamudi K; Yassa AE
    J Oncol Pharm Pract; 2021 Jan; 27(1):253-257. PubMed ID: 32611269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plateletpheresis for postsplenectomy rebound thrombocytosis in a patient with chronic immune thrombocytopenic purpura on romiplostim.
    Raval JS; Redner RL; Kiss JE
    J Clin Apher; 2013 Aug; 28(4):321-4. PubMed ID: 23450778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim.
    Al-Samkari H; Van Cott EM; Kuter DJ
    Ann Hematol; 2019 Mar; 98(3):581-588. PubMed ID: 30446804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care.
    Stasi R; Murali M; Michel M; Viallard JF; Giagounidis A; Janssens A; Legg J; Deuson R; Danese MD
    Int J Hematol; 2012 Jul; 96(1):26-33. PubMed ID: 22562409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful treatment of Immune Thrombocytopenic Purpura (ITP) with the thrombopoietin-mimetic romiplostim.
    Meletis J; Katsandris A; Raptis SD; Mantzourani M
    Med Sci Monit; 2010 Aug; 16(8):CS100-2. PubMed ID: 20671616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy.
    Mitsuhashi K; Ishiyama M; Imai Y; Shiseki M; Mori N; Teramura M; Seshimo A; Motoji T
    Br J Haematol; 2012 Sep; 158(6):798-800. PubMed ID: 22758388
    [No Abstract]   [Full Text] [Related]  

  • 36. Effectiveness and safety of romiplostim among patients with newly diagnosed, persistent and chronic ITP in routine clinical practice in central and Eastern Europe: an analysis of the PLATON study.
    Skopec B; Sninska Z; Tzvetkov N; Ivanushkin V; Björklöf K; Hippenmeyer J; Mihaylov G
    Hematology; 2021 Dec; 26(1):497-502. PubMed ID: 34238136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful early romiplostim use in a case of severe immune thrombocytopenia with critical carotid arterial injury.
    Watanabe R; Tabayashi T; Tomikawa T; Sagawa M; Anan-Nemoto T; Kimura Y; Takahashi Y; Tokuhira M; Otaki S; Oi H; Sawano M; Sugiyama S; Kizaki M
    Int J Hematol; 2017 Jan; 105(1):100-103. PubMed ID: 27709451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia.
    Grainger JD; Kühne T; Hippenmeyer J; Cooper N
    Ann Hematol; 2021 Sep; 100(9):2143-2154. PubMed ID: 34308495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eltrombopag. Idiopathic thrombocytopenic purpura after treatment failure: romiplostim is a better option.
    Prescrire Int; 2010 Feb; 19(105):15. PubMed ID: 20455333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.